Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512744 | 0.85 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19KMT2ANPSR1 | |
| SCHEMBL7398748 | 0.85 | ENPP2 (0.61) | CYP1A2CYP2C9CYP2C19KMT2ANPSR1 | |
| SCHEMBL1029072 | 0.82 | CCNB2 (0.62) | CYP1A2CYP2C9CYP2C19KMT2AALDH1A1 | |
| SCHEMBL17894466 | 0.78 | ENPP2 (0.56) | CYP1A2CYP2C9CYP2C19KMT2ANPSR1 | |
| SCHEMBL8344558 | 0.78 | MAOB (0.50) | CYP1A2CYP2C9CYP2C19KMT2AALDH1A1 | |
| SCHEMBL11083786 | 0.76 | ENPP2 (0.66) | CYP1A2CYP2C9CYP2C19KMT2ANPSR1 | |
| SCHEMBL12301128 | 0.76 | ENPP2 (0.66) | ENPP2CYP3A4MAPTL3MBTL1MAOB | |
| SCHEMBL2284712 | 0.76 | ENPP2 (0.54) | CYP1A2CYP2C9CYP2C19KMT2ANPSR1 | |
| SCHEMBL8708519 | 0.75 | CCNB2 (0.55) | CYP1A2CYP2C9CYP2C19KMT2ANPSR1 | |
| SCHEMBL8708521 | 0.75 | CCNB2 (0.55) | CYP1A2CYP2C9CYP2C19KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
| EP-1345618-B1 | CHLORZOXAZONE FOR THE TREATMENT OF PSORIASIS | SWITCH BIOTECH AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| EP-1345618-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | Switch Biotech Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002053171-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | MMP1, COL2A1, FN1 | CYP1A2 3901/4885CYP2C9 4804/4885CYP2C19 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.